By Jim O’Neill
October 15, 2026
The global economy currently stands at a perilous intersection. While policymakers obsess over short-term fiscal volatility and the mechanics of interest rates, a far more insidious threat—antimicrobial resistance (AMR)—is quietly eroding the foundations of modern medicine and long-term economic prosperity. As I observed during recent high-level discussions in London, there is a dangerous tendency for experts to operate within rigid silos, failing to recognize that our current fiscal incentives are not merely broken; they are actively exacerbating the existential risk posed by drug-resistant bacteria.
The Core Conflict: Financial Engineering vs. Biological Survival
The fundamental failure of our current economic model lies in the mispricing of innovation. In the pharmaceutical sector, tax policies and market structures have incentivized "financial engineering"—the prioritization of share buybacks, mergers, and the development of high-margin chronic disease treatments—over the urgent, high-risk endeavor of developing novel antibiotics.
Antibiotics are, by their nature, meant to be used sparingly to remain effective. This inherent limitation makes them a "bad" investment for traditional pharmaceutical business models, which rely on volume. Consequently, we are facing a market failure of catastrophic proportions. While the threat to public health is widely acknowledged, the economic dimension—the "perverse incentives" that drive capital away from the laboratory bench—remains critically under-addressed.
Chronology of the Crisis: A Decade of Neglect
To understand how we reached this point, we must look at the trajectory of the AMR crisis over the last decade:
- 2014-2016: The initial global recognition of the AMR threat led to the commissioning of the Review on Antimicrobial Resistance. During this period, the world briefly flirted with the idea of "market entry rewards" to decouple the volume of antibiotic use from the profitability of their development.
- 2018-2021: The COVID-19 pandemic temporarily shifted focus, but also highlighted the fragility of global supply chains and the danger of ignoring infectious disease threats. Ironically, while billions were funneled into vaccine development, the antibiotic pipeline continued to atrophy.
- 2023: Several major pharmaceutical firms exited the infectious disease space, citing insufficient return on investment (ROI) compared to oncology or rare disease research.
- 2025-2026: Recent data indicates a surge in "superbug" infections that are increasingly resistant to last-resort treatments, leading to longer hospital stays, higher mortality rates, and a measurable drag on global GDP.
Supporting Data: The Economic Toll
The numbers are stark. Antimicrobial resistance is not just a clinical issue; it is a macroeconomic anchor.
- Direct Costs: Projections suggest that if left unchecked, AMR could cost the global economy upwards of $100 trillion by 2050 in lost output. The burden of treating resistant infections is already pushing healthcare systems to the brink of insolvency.
- Productivity Loss: Beyond the hospital bills, the secondary economic effects—absenteeism, long-term disability, and the loss of a productive workforce—are staggering. When routine surgeries and medical procedures (such as chemotherapy or organ transplants) become too risky to perform due to the threat of untreatable infection, the entire structure of modern healthcare collapses.
- The "Innovation Gap": Since 2010, the number of new antibiotic classes entering the market has remained near zero. Contrast this with the exponential growth in other sectors of the biotech industry, and the impact of the current tax regime becomes clear. We have created an environment where it is more profitable to repackage existing drugs than to discover the next penicillin.
The Parallel Crisis: Public Spending and Moral Hazard
The same logic that plagues antibiotic development is mirrored in the sphere of public finance. We are witnessing a pattern of "out-of-control public spending" that ignores long-term value creation.
In many developed economies, fiscal policy is dictated by political cycles rather than strategic investment. Just as pharmaceutical companies chase the "quick win" of stock buybacks, governments chase the "quick win" of debt-fueled consumption, ignoring the structural deficits that hinder future growth.
When public spending is directed toward servicing current consumption rather than investing in the "infrastructure of survival"—which includes everything from R&D into public health to climate resilience—we are effectively borrowing from the future to pay for the present. The result is a dual-crisis: we are depleting our fiscal ammunition while simultaneously rendering our medical toolkit obsolete.
Official Responses and the Policy Stagnation
International bodies, including the G7 and the World Health Organization (WHO), have issued numerous statements of concern. Yet, the disconnect between rhetoric and action remains wide.
- The "Pull" Incentive Debate: There is growing consensus among economists that we need a "Pull" mechanism—guaranteed market entry rewards that pay developers for the value of the antibiotic, not the volume sold. While some pilot programs (such as the UK’s subscription-style model, the "Netflix" model) have gained traction, they are currently too small to offset the massive disincentives elsewhere in the market.
- Regulatory Inertia: Regulatory bodies have struggled to balance the need for rapid approval of new drugs with the rigorous safety standards required for antimicrobials. This "regulatory friction" acts as another barrier to entry for smaller, more agile biotech firms that might otherwise fill the pipeline.
Implications: A Looming Paradigm Shift
If we continue to ignore the structural alignment of our economic systems with our survival needs, the implications are severe:
1. The Erosion of Modern Medicine
Without effective antibiotics, the risks associated with elective surgery, C-sections, and joint replacements will skyrocket. The mortality rate for common infections could return to pre-1940s levels, fundamentally altering human life expectancy and quality of life.
2. Economic Stagnation
A population that is perpetually sick or terrified of medical intervention is not a productive one. The drag on GDP will be felt most acutely in emerging markets, which are the least equipped to deal with the surge in healthcare costs, potentially leading to increased global inequality and migration crises.
3. The Need for Fiscal Reform
We must reform tax codes to penalize financial engineering that undermines essential innovation. Tax credits should be explicitly tied to R&D in critical public health sectors. Furthermore, public spending must shift toward a "strategic resilience" framework. Governments must treat antibiotic research as a global public good—comparable to defense or infrastructure—rather than a market commodity.
Conclusion: Connecting the Dots
The two conversations I referenced earlier were, on the surface, about disparate topics: the future of pharmaceutical investment and the sustainability of government spending. Yet, the underlying theme was identical. We have created a global system that rewards short-term balance sheet optimization while neglecting the long-term, existential investments required to keep our civilization functioning.
The silos must come down. We need a coordinated approach where central bankers, health ministers, and tax authorities work in tandem to align fiscal incentives with the reality of our biological constraints. If we do not, the "silent pandemic" of antimicrobial resistance will eventually become a loud, chaotic, and devastating reality that no amount of financial engineering will be able to solve.
The time for incrementalism has passed. We require a radical realignment of capital toward the common good. The cost of doing nothing is no longer just an economic forecast; it is a health catastrophe waiting to happen. The question is not whether we can afford to invest in the next generation of antibiotics, but whether we can afford the consequences of our current, misplaced priorities.
